PCVX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Vaxcyte Inc (PCVX) is not a strong buy for a beginner, long-term investor at this moment. While the company has promising catalysts in its pipeline, such as the Phase 3 trials for VAX-31 and positive analyst ratings, the recent financial performance, including significant losses and missed earnings estimates, raises concerns. Additionally, no strong trading signals or significant insider/congress trading trends support immediate action. A hold is recommended until more favorable entry points or positive developments emerge.
The technical indicators show a mixed picture. The MACD is positive and contracting, suggesting a potential bullish trend, while the RSI is neutral at 59.152. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the stock is trading above its pivot point of 58.511, with resistance at 63.236. However, the stock trend analysis suggests a 40% chance of a decline in the short term.
Strong Phase 2 data for VAX-31 and ongoing Phase 3 trials.
Positive analyst sentiment with multiple buy ratings and raised price targets.
Stable policy environment for pneumococcal vaccines.
Significant Q4 net loss of $246.5 million and missed earnings estimates.
Proposed $500 million public offering, which could dilute current shareholders.
Stock trend analysis indicates a potential short-term decline.
In Q4 2025, the company reported no revenue growth (0% YoY) and a net loss of $246.5 million, which improved by 79.83% YoY. EPS also improved by 79.21% YoY to -$1.81, but the company remains unprofitable.
Analysts are generally bullish on Vaxcyte, with multiple buy ratings and raised price targets (e.g., TD Cowen to $75, BTIG to $89, Needham to $110). The focus is on the potential of VAX-31 as a best-in-class pneumococcal vaccine, with upcoming Phase 3 data as a key catalyst.
